Radiopharmaceuticals represent the next generation of cancer treatment — acting like autonomous micro-drones that precisely detonate a warhead at the tumor cell — and Aktis Oncology's mini-protein platform could be worth $10 billion if even one program reaches market.

Oleg Nodelman pitches Aktis Oncology, a radiopharmaceutical company using mini-proteins to deliver radioactive payloads precisely to cancer cells. The platform has a strong moat (radioisotope supply is US-sourced and China can't easily replicate it), known validated targets (Nectin-4, B7H3), and de-risking via imaging verification. He values it at ~$10B/$200 per share if one program succeeds — a 10x from current valuation. ✦ AI generated

Oleg Nodelman · All-In Podcast · 2026-06-12 · original ↗

Modern day radiopharmaceuticals. Like a swarm of micro drones, small enough to navigate the bloodstream and find their target by molecular recognition, then detonate a precisely sized warhead with a blast radius of 100 microns or the diameter of a single cell. An autonomous assassination with the force of a bunker buster and minimum collateral damage. The company I'm going to tell you about today is Actus Oncology. The ticker is AKTS. The company has a billion dollar market cap, a $500 million enterprise value, and a stockpile of cash which should last them over three years. Long past critical milestones that are coming next year. For earlier stage opportunities like this, we like to triangulate. We think Actis could be worth $10 billion or $200 per share if even one of their programs makes it to market. And in this case, you have a lot of outs.

verbatim transcript · starts at 27:18